Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum on Thursday, September 24, 2026, at 8:50 AM Eastern Time. A live webcast and subsequent replay of the event will be available in the Investor Relation.

Business Wire • Sep 16, 2026

Bio-Rad: Favorable Read-Across From Investor Event

Bio-Rad Laboratories (BIO) remains a Buy, after my assessment of relevant corporate disclosures at the recent Wells Fargo Healthcare conference. Management targets long-term operating margins of 20%, with intermediate milestones in the mid-teens, outpacing consensus expectations. Margin drivers include cost rationalization, AI-driven efficiencies, and a shift toward higher-margin consumables revenue.

Seeking Alpha • Sep 10, 2026

Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha • Sep 9, 2026

Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?

Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 3, 2026

Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo's 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relati.

Business Wire • Aug 31, 2026

Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?

BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.

Zacks Investment Research • Aug 21, 2026

Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?

BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.

Zacks Investment Research • Aug 20, 2026

Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock

Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Zacks Investment Research • Aug 10, 2026

Bio-Rad Laboratories Q2 Earnings Call Highlights

Bio-Rad Laboratories NYSE: BIO reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral basis, as continued softness in academic research markets weighed on its Life Science segment.

MarketBeat • Aug 5, 2026

Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 5, 2026